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Background: Imatinib is tyrosine kinase inhibitor (TKI) and as a targeted anti-cancer agent has significantly changed chronic myeloid 
leukemia (CML) prognosis and patient survival. Currently TKI is the main therapy in CML Philadelphia chromosome-positive 
(Ph-positive) cases. When generics of imatinib appeared in the pharmaceuticals market, reimbursement policies in many countries 
switched to using generics or encouraged use of generic imatinib to lower the expenses. Cost savings were substantial; however, for 
doctors and CML patients the efficacy, safety and quality of generic imatinib were an issue of concern. Objective: Since the global 
number of CML patients, who in the future will have to switch from original imatinib to generic imatinib, is high, the aim of study was 
to monitor, whether during 24 months of generic imatinib usage patients maintain the achieved major molecular response (MMR) 
or whether the treatment results are inferior. Methods: We conducted a retrospective study, which included CML patients, who 
were above 18 years of age and who until May 2013 had used at least for 2 years (24 months) the original imatinib, and following 
that used at least for 24 months one of the generic imatinib medicines. In 2013, before switching to generic imatinib, all patients had 
reached MMR in accordance with European LeukemiaNet (ELN) Guidelines. Every three months blood count, BCR-ABL fusion 
gene (BCR-ABL), biochemical analysis and side effect were monitored. Results: Our study proved that CML patients, who had 
achieved MMR by original imatinib therapy, retained MMR during 24 months of generic imatinib therapy. Nobody was switched 
to second line generation TKI. During observation period neither haematological, nor non-hematological toxicity was found. 
Conclusion: Our study proved that CML patients, who had achieved MMR by original imatinib therapy, retained MMR during 
24 months of generic imatinib therapy. This demonstrates that generic imatinib is not inferior to original imatinib. As to expenses, 
the annual costs of generic imatinib are lower by 96%, which is a significant benefit to health-care financing.
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The last two decades have witnessed fast prog-
ress in the treatment of haematological diseases. 
One of the examples is imatinib (Gleevec, Novar-
tis), which was for the first time used for treating 
chronic myeloid leukemia (CML) in 1998. Imatinib 
is tyrosine kinase inhibitor (TKI) and as a targeted 
anti-cancer agent has significantly changed CML 
prognosis and patient survival. Currently TKI 
is the main therapy in CML Philadelphia chromo-
some-positive (Ph-positive) cases, it is leading 
to a decline in annual mortality rates from 10–20% 
to 2% and has improved the estimated 10-years 
survival from less than 20% to more than 80%, and 
the number of patients, who have attained treat-
ment-free remission, keeps increasing. Alongside 
these achievements, the costs of successful CML 
treatment also increased. When generics of ima-
tinib appeared in the pharmaceuticals market, 
reimbursement policies in many countries switched 
to using generics or encouraged use of generic 
imatinib to lower the expenses. Cost savings were 
substantial; however, for doctors and CML patients 
the efficacy, safety and quality of generic imatinib 
were an issue of concern.
The first TKI — imatinib mesylate (imatinib) 
(Glivec; Novartis, Basel, Switzerland) was registered 
for use in Europe in 2002. In Latvia imatinib for CML 
patients was included in the list of medicines reim-
bursed by the state in 2006 October. Initially imatinib 
was reimbursed in the presence of following CML indi-
cations: children with CML all phases and second line 
treatment for adult CML chronic phase (CP) patients. 
From May 2013 the original Glivec was substituted 
by generic imatinib in the state reimbursement medi-
cines list. Tibaldix and Meaxin were the first generic 
imatinibs used in Latvia. The registered indications for 
using the medicines did not coincide with the ones 
for which the state reimbursed the use of it. However, 
considering the great difference in prices, the State 
reimbursement system ignored it, providing that all 
indications for using imatinib that have ever been 
registered were applicable also to these medicines. 
Patients had no choice — the state reimbursement 
system paid only for generic imatinib. Only one pa-
tient with CML CP continued to pay himself for the 
original drug Gleevec. In this country the purchase 
price of medicines is reviewed every 3 months, and 
if the price of a medicine belonging to a certain 
group changes, then the state reimburses in 100% 
amount only the cheapest medicine. Thus, not all 
patients received all the time generic imatinib of the 
same producer; many received various generic ima-
tinibs in their treatment. Table 1 shows those generic 
imatinibs that were on the reimbursement list from 
May 2013 until March 2016, as well their marketing 
authorisation holder and the state.
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Table 1. Generic imatinibs
Generic imatinib Marketing authorisation holder, state
Tibaldix Pharma Swiss, the Czech Republic
Meaxin KRKA, Slovenia
Imatinib Teva Teva, the Netherlands
Itivas Briz, Latvia
Imatinib Accord Accord Healthcare Limited, the UK
Imatinib Sano Swiss Sano Swiss, Lithuania
Since the global number of CML patients, who 
in the future will have to switch from original imatinib 
to generic imatinib, is high, the aim of study was 
to monitor, whether during 24 months of generic 
imatinib usage patients maintain the achieved major 
molecular response (MMR) or whether the treatment 
results are inferior, to monitor also side effects, fre-
quency of them. If the treatment results are not inferior, 
to compare the costs of medicines.
MATERIALS AND METHODS
We conducted a retrospective study in Riga East 
Clinical University Hospital Chemotherapy and Hemato-
logy Clinic, which included all CML patients, who were 
above 18 years of age and who until May 2013 had used 
at least for 2 years (24 months) the original imatinib, and 
following that used at least for 24 months one of the 
generic imatinib medicines. In 2013, before switching 
to generic imatinib, all patients had reached MMR in ac-
cordance with ELN Guidelines [1, 2]. The study design, 
patients’ information and consent forms were approved 
by the Ethic Commitee of the Riga Stradins University. 
All patients had agreed to data analysis.
Criteria for including in the study:
•	patients > 18 years;
•	CP at the moment of diagnosing CML, Ph-positive;
•	until switching to using generic medicines, have 
used at least for 24 months the original medicine 
(Imatinib, Novartis);
•	before switching to generic imatinib MMR was 
achieved in accordance with ELN recommendation 
[1].
In addition, data on:
•	age at the moment of diagnosing CML;
•	age, when the therapy with generic imatinib was 
started;
•	chemotherapy and its duration before switching 
to generic imatinib were collected.
During 24 months’ therapy the following parame-
ters were monitored:
•	dynamics of full blood count every three months 
from start of generic imatinib till 24 months (3; 6; 
9; 12; 15; 18; 21; 24) after beginning to use generic 
imatinib;
•	dynamics of BCR-ABL every three months after 
beginning to use generic imatinib;
•	dynamics of commonly used biochemical analysis 
(creatinine, glomerular filtration rate, bilirubin, 
ASAT, ALAT) and side effects every three months.
RESULTS AND DISCUSSION
25 patients with CML CP were included in the 
study, of which 11 were women and 14 were men. 
At the moment of diagnosing CML patients were from 
18 to 84 years old. They started using generic imatinib 
in the age from 20 to 87 years (Table 2).
Table 2. CML patients’ data
Gender/number Mean age at the time of diagnosis
Mean age of the time  
of starting generic imatinib
Female, n = 11 54.10 58.38
Male, n = 14 50.33 55.07
All patients included in the study had received 
at least 24 months of original imatinib therapy, prior 
to which 8 patients had received treatment with hy-
droxycarbamidum for mean 7.5 months, and 17 pa-
tients for mean 13 months had received treatment with 
hydroxycarbamidum combined with alpha-interferon.
Patients included in the observational study received 
a daily dose of 400 mg generic imatinib, and used 
the medicine regularly. All patients during 24 months 
retained MMR (Table 3); nobody was switched to se-
cond line generation TKI. During the observation period 
neither haematological, nor non-hematological toxic-
ity was found. 2 patients complained of the generic 
imatinib 400 mg pill being too large, making it difficult 
to swallow it. After generic producer was replaced, 
no more complaints were received.
Table 3. BCR-ABL (%) results during treatment with generic imatinib
Patient 
Nr 0 months* 3 months 6 months 12 months 24 months
1 0.0013 0.0046 0.0097 0.0018 0.00096
2 0.01 0.0013 0.00056 0.00031 0.0002
3 0.0049 0.00061 0.0029 0.0011 0.0002
4 0.0019 0.0019 0.00044 0.00001 0.00001
5 0.011 0.0084 0.0012 0.006 0.002
6 0.0018 0.001 0.00067 0.00075 0.0003
7 0.01 0.009 0.0096 0.0034 0.0023
8 0.0012 0.0098 0.0021 0.0067 0.00069
9 0.01 0.006 0.00096 0.0003 0.0012
10 0.011 0.003 0.0011 0.0073 0.00087
11 0.0012 0.0037 0.0032 0.0014 0.00033
12 0.0013 0.0026 0.005 0.0013 0.0014
13 0.01 0.0062 0.0035 0.0075 0.00013
14 0.0013 0.0035 0.0016 0.009 0.0042
15 0.0012 0.0017 0.0062 0.0009 0.0001
16 0.007 0.0028 0.0022 0.00073 0.0001
17 0.0077 0.0071 0.00021 0.00001 0.00001
18 0.002 0.007 0.007 0.008 0.00023
19 0.0012 0.0022 0.00034 0.0001 0.0001
20 0.0015 0.00057 0.0013 0.0034 0.0042
21 0.0084 0.012 0.0001 0.0022 0.0048
22 0.00089 0.00077 0.0023 0.00088 0.0006
23 0.0042 0.0089 0.009 0.0089 0.0003
24 0.0052 0.0043 0.0011 0.00043 0.00022
25 0.0073 0.0013 0.0024 0.0031 0.0006
Note: *BCR-ABL results before switching to generic imatinib; and after 3, 
6, 12 and 24 months.
We determined the average level of MMR among 
all patients in each control period. Fig. 1 shows the 
tendency of MMR changing for each control period 
during 24 months. The obtained data reflect the level 
of MMR, after switching to generic imatinib, is be-
low 0.01%. Fig. 2 shows each patient’s MMR level 
at 0; 12 and 24 months.
Since the appearance of the first TKI imatinib ge-
neric medicines there have been doubts and concerns 
about their efficacy, safety and quality. Many patients 
had been using the original imatinib for years, so they 
also were doubtful. In the medical press a number 
of publications express this concern; however, they 
comprise only very general data that could support 
or reject this opinion [3–7].
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On 1 April 2013 the Indian Supreme Court upheld 
the decision of the Indian Patent Office to refuse grant-
ing patent for Novartis imatinib mesylate (Glivec). The 
patent application failed to meet the requirements 
for patentability under the Indian law [8]. And already 
in 2013 the first report on the experience of using ge-
neric imatinib in India, in Mumbai, 2002–2008, was 
published [9]. It was a retrospective study of 1000 CML 
CP patients, of which 237 patients used generic ima-
tinib. The study showed that complete cytogenetic 
response (CCyR) was similar in both the group that 
used the original and the group using generic ima-
tinib in patients, who were first diagnosed with CML 
CP. A number of reports on using generic imatinib 
to treat patients first diagnosed with CML CP patients 
have been published, for example, Jiang Q with 
co-authors [10] has published data about 107 first 
diagnosed CML CP patients, who as the primary 
therapy received generic imatinib for 3 months, and 
54 of which had received it for 6 and more months. 
After 3 and 6 months their CCyR was assessed, which 
was, respectively, 98.1% and 100%, CCyR — 35.1% 
and 71.8%, but MMR was diagnosed in, respectively, 
10.4 and 33.3% [10]. The researchers concluded that 
results revealed excellent early haematological, cyto-
genetic and molecular response and safety. A similar 
study was conducted by Demirkan et al. [11] about 
first diagnosed CML CP patients in Izmir (Turkey), 
of which 14 received generic imatinib and 21 received 
the original medicine, all patients were able to achieve 
complete hamatological response (CHR) at the 
3rd month, MMR rates at the 6th month were 35.7% and 
31.6%, which showed that generic formulation was not 
inferior to the original imatinib. The study of Algeria 
CML patients, who started therapy with imatinib, also 
demonstrated that generic imatinib was effective and 
safe treatment option [12].
Our study comprised patients, who used generic 
imatinib after MMR had been achieved by using the 
original imatinib. Upon switching to generic imatinib 
all patients retained MMR during 24 months of ob-
servation. This demonstrates that generic imatinib 
is not inferior to original imatinib. There are few similar 
studies researching the use of generic imatinib fol-
lowing therapy with the original imatinib. One of such 
studies is the researched published in 2015 about CML 
patients after the Public Health System in Brazil started 
reimbursing generic formulation in 2013. Patients with 
CML, who had achieved MMR with the original ima-
tinib therapy, were studied, patients’ daily dose was 
400 mg, BCR-ABL was monitored every 3 to 6 months. 
Of 40 patients, 24 (60%) had no variation on sequen-
tial analysis and 13 (32.5%) had one or two variation 
of BCR-ABL between 0.1% to 1.16%, but re-achieved 
MMR, 2 patients lost MMR due to compliance is-
sue [7]. The researches noted that generic imatinib 
was safe and kept the efficacy.
A study that arrives at negative conclusions about 
generic imatinib is from Iraq, Alwan et al. [13] prospec-
tively evaluated the response of patients with CML 
in CP in one institution. Patients with CHR (n = 126) 
switched from branded imatinib to an imatinib copy 
drug. Subsequently, all patients switched back to the 
branded imatinib. Many patients in this study had a loss 
of hematologic response and experienced tolerabi-
lity issues with the imatinib copy drug. Hematologic 
response and tolerability improved upon retreatment 
with branded Glivec. There have been many objections 
to this study, since it lacked standardized control, and 
no discussion of these data has been published [5, 6].
Ostojic A. et al. has published a study on imatinib 
plasma concentration in the case of original and ge-
neric imatinib [14] 24 patients were included in the 
study, 6 and 13, respectively, had used various generic 
imatinibs, but 5 patients had used both. The study con-
cluded that median imatinib plasma concentration, 
when taken at equivalent doses, in imatinib generics 
was bioequivalent and comparable in clinical efficacy.
All studies have noted substantial savings in the 
treatment costs [7, 8, 11, 14]. The financial gain in our 
study is also substantial — comparison of monthly 
costs of 400 mg per day therapy shows that the first 
decrease in costs in May 2013 was 86.6%, but cur-
rently the monthly costs of generic imatinib is even 
by 96% lower compared to the costs of original imatinib 
(Gleevec), thus at present it is 4%. The annual costs 
of original imatinib therapy (400 mg per day) was 
29,835.36 EUR, of generic imatinib — 1,238.4 EUR.
CONCLUSION
Our study proved that CML patients, who had 
reached MMR by original imatinib therapy, retained 
MMR during 24 months of generic imatinib therapy. 
Fig. 2. Patient’s BCR-ABL levels during observation period.
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Fig. 1. Tendency of MMR changing during 24 months period.
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This demonstrates that generic imatinib is not inferior 
to original imatinib. As to expenses, the annual costs 
of generic imatinib are lower by 96%, which is a sig-
nificant benefit to health-care financing.
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